A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell Lymphoma
Plain-language summary
This study uses molecular subtyping to guide treatment selection for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome. The goal is to match patients to more effective therapies based on their lymphoma subtype. This trial does not currently have sites in the United States.
Who can join (key eligibility)
- Age 18 Years to 75 Years years
- See full trial listing for complete eligibility
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
molecular subtype based treatment (OTHER): The immunohistochemistry algorithm established by the previous research group was used to determine the molecular subtype, and the corresponding treatment plan was selected according to the subtype. Such as for TCyEM patients, interferon-based immunomodulatory therapy was selected, and TCM-type patients were treated with retinoids.
molecular subtype based treatment
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details